CORRADINI, PAOLO
CORRADINI, PAOLO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL
2025 R. Durmo, S. Chauvie, F. Fallanca, F. Bergesio, A. Pinto, I. Del Giudice, M. Coscia, P. Corradini, E. Angelucci, P. Tosi, R. Freilone, F. Ballerini, A. Bari, D. Pastore, P.L.L. Zinzani, S.A.M. Bolis, L. Flenghi, A. Liso, J. Olivieri, L. Marcheselli, M. Merli, A. Versari, L. Guerra, S. Luminari
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD
2025 C. Rusconi, A. Barone, A. Visentin, B. Bianchi, V.R. Zilioli, A. Bernardelli, S. Iadecola, E. Olivari, F.G. Rossi, M. Gotti, C. Cecchetti, B. Puccini, S. Franceschetti, A. Molteni, S. Steffanoni, F. Marino, A. Vanazzi, A. Guidetti, M. Merli, F. Mazzon, A. Marchetti, A. Cellini, C. Muzi, R. Miceli, C. Visco, A. Re, P. Corradini
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
2025 F. Stella, A. Chiappella, M. Magni, F. Bonifazi, C. De Philippis, M. Musso, I. Cutini, S. Ljevar, A.M. Barbui, M. Farina, M. Martino, M. Massaia, G. Grillo, P. Angelillo, B. Botto, F. Patriarca, M. Krampera, L. Arcaini, M.C. Tisi, P. Zinzani, F. Sorà, S. Bramanti, M. Pennisi, C. Carniti, P. Corradini
Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study
2025 F. Stella, M. Pennisi, A. Chiappella, B. Casadei, S. Bramanti, S. Ljevar, P. Chiusolo, A.D. Rocco, M.C. Tisi, P. Angelillo, I. Cutini, M. Martino, A. Barone, F. Bonifazi, A. Santoro, F. Sorà, M. Novo, A.M. Barbui, D. Russo, M. Musso, G. Grillo, M. Krampera, J. Olivieri, L. Brunello, F. Cavallo, M. Massaia, L. Arcaini, L. Farina, P. Zinzani, R. Miceli, P. Corradini
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
2025 C. Papayannidis, E. Petracci, P. Zappasodi, N. Fracchiolla, F. Ciceri, C. Sartor, E. Roncoroni, F. Di Raimondo, D. Mattei, M.B. Giannini, F. Lanza, M. Gottardi, M.I. Del Principe, E. Borlenghi, M. Fumagalli, D. Vallisa, S. Sica, N. Di Renzo, F. Fabbiano, E. Todisco, P. de Fabritiis, M. Luppi, F. Passamonti, P. Corradini, F. Petruzziello, F. Pane, F. Ferrara, G. Mambelli, R. Volpi, F. Frabetti, C. Zingaretti, G. Marconi, G. Martinelli
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
2024 G. Cavallaro, A. Grassi, C. Pavoni, M.C. Micò, A. Busca, I.M. Cavattoni, S. Santarone, C. Borghero, A. Olivieri, G. Milone, P. Chiusolo, P. Musto, R. Saccardi, F. Patriarca, F. Pane, G. Saporiti, P. Rivela, E. Terruzzi, R. Cerretti, G. Marotta, A.M. Carella, A. Nagler, D. Russo, P. Corradini, P. Bernasconi, A.P. Iori, L. Castagna, N. Mordini, E. Oldani, C. Di Grazia, A. Bacigalupo, A. Rambaldi
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
2024 B. Ziccheddu, C. Giannotta, M. D'Agostino, G. Bertuglia, E. Saraci, S. Oliva, E. Genuardi, M. Papadimitriou, B. Diamond, P. Corradini, D. Coffey, O. Landgren, N. Bolli, B. Bruno, M. Boccadoro, M. Massaia, F. Maura, A. Larocca
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries
2024 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Corradini, P. Russo
Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
2024 S. Bramanti, D. Mannina, A. Chiappella, B. Casadei, C. De Philippis, L. Giordano, P. Navarria, P. Mancosu, D. Taurino, M. Scorsetti, C. Carlo-Stella, P. Zinzani, A. Santoro, P. Corradini
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024 F. Stella, A. Chiappella, B. Casadei, S. Bramanti, S. Ljevar, P. Chiusolo, A. Di Rocco, M.C. Tisi, M.G. Carrabba, I. Cutini, M. Martino, A. Dodero, F. Bonifazi, A. Santoro, F. Sorà, B. Botto, A.M. Barbui, D. Russo, M. Musso, G. Grillo, M. Krampera, J. Olivieri, M. Ladetto, F. Cavallo, M. Massaia, L. Arcaini, M. Pennisi, P.L. Zinzani, R. Miceli, P. Corradini
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2024 A. Pulsoni, S. Ferrero, M.E. Tosti, S. Luminari, A. Dondi, F. Cavallo, F. Merli, A.M. Liberati, N. Cenfra, D. Renzi, M. Zanni, C. Boccomini, A.J.M. Ferreri, S. Rattotti, V.R. Zilioli, S.A. Bolis, P. Bernuzzi, G. Musuraca, G. Gaidano, T. Perrone, C. Stelitano, A. Tucci, P. Corradini, S. Bigliardi, F. Re, E. Cencini, C. Mannarella, D. Mannina, M. Celli, M. Tani, G. Annechini, G.M. Assanto, L. Grapulin, A. Guarini, M. Cavalli, L.A. De Novi, R. Bomben, E. Ciabatti, E. Genuardi, D. Drandi, I. Della Starza, L. Arcaini, U. Ricardi, V. Gattei, S. Galimberti, M. Ladetto, R. Foà, I. Del Giudice
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study
2024 A. Barone, A. Chiappella, B. Casadei, S. Bramanti, S. Ljevar, P. Chiusolo, A. Di Rocco, M.C. Tisi, A.M. Barbui, M. Farina, L. Brunello, M.C. Di Chio, M. Novo, M. Musso, J. Olivieri, G.E. Trotta, A. Dodero, A. Aiello, P. Corradini
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
2024 A. Chiappella, B. Casadei, P. Chiusolo, A. Di Rocco, S. Ljevar, M. Magni, P. Angelillo, A.M. Barbui, I. Cutini, A. Dodero, F. Bonifazi, M.C. Tisi, S. Bramanti, M. Musso, M. Farina, M. Martino, M. Novo, G. Grillo, F. Patriarca, G. Zacchi, M. Krampera, M. Pennisi, E. Galli, M. Martelli, A.J.M. Ferreri, S. Ferrari, R. Saccardi, A. Bermema, A. Guidetti, R. Miceli, P.L. Zinzani, P. Corradini
Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel
2023 C. Girmenia, F. Ciceri, P. Corradini, A. Cuneo, F. D'Ancona, P. Musto, A.M. Risitano, M.T. Voso, A. Venditti, G. Barosi
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
2023 A. Dodero, S. Bramanti, M. Di Trani, M. Pennisi, S. Ljevar, A. Chiappella, M. Massimo, A. Guidetti, F. Corrado, P.M. Nierychlewska, A. Di Rocco, D. Lorenzini, R. Daoud, C. De Philippis, A. Santoro, C. Carlo-Stella, P. Corradini
Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients
2023 M. D'Agostino, G. Bertuglia, D. Rota-Scalabrini, A. Belotti, S. Morè, P. Corradini, S. Oliva, A. Ledda, M. Grasso, V. Pavone, S. Ronconi, I.D. Vincelli, S. Ballanti, C. Velluti, C. Cellini, A. Gozzetti, A.D. Palmas, B. Gamberi, K. Mancuso, L. Paris, R. Zambello, M.T. Petrucci, B. Bruno, P. Musto, F. Gay
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
2023 F. Stella, V. Marasco, G.V. Levati, A. Guidetti, A. De Filippo, M. Pennisi, C. Vismara, R. Miceli, S. Ljevar, C. Tecchio, N. Mordini, G. Gobbi, L. Saracino, P. Corradini
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
2023 K. Rejeski, M. Subklewe, M. Aljurf, E. Bachy, A. Balduzzi, P. Barba, B. Bruno, R. Benjamin, M.G. Carrabba, C. Chabannon, F. Ciceri, P. Corradini, J. Delgado, R. Di Blasi, R. Greco, R. Houot, G. Iacoboni, U. Jäger, M.J. Kersten, S. Mielke, A. Nagler, F. Onida, Z. Peric, C. Roddie, A. Ruggeri, F. Sánchez-Guijo, I. Sánchez-Ortega, D. Schneidawind, M. Schubert, J.A. Snowden, C. Thieblemont, M. Topp, P.L. Zinzani, J.G. Gribben, C. Bonini, A. Sureda, I. Yakoub-Agha
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)
2023 M. Breccia, P.P. Olimpieri, S. Celant, O.M. Olimpieri, F. Pane, A. Iurlo, V. Summa, P. Corradini, P. Russo
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy
2023 A. Guidetti, A. Dodero, A. Lorenzoni, S. Pizzamiglio, G. Argiroffi, A. Chiappella, F. Bagnoli, V. Marasco, C. Carniti, C. Monfrini, E. Seregni, M. Pennisi, P. Verderio, A. Alessi, P. Corradini